Net loss widened significantly to $128.9M due to unrealized equity losses and revenue collapse.
Revenue dropped from $32.7M to $4.5M while R&D expenses increased by 10%.
Carries $108.5M in royalty-sale liabilities with high effective interest rates.
Pending BLA submissions for partner products provide potential binary upside.
Xencor's first quarter of 2026 presents a stark contrast between long-term platform potential and immediate financial volatility. The company's ability to fund its operations through 2028 provides a critical safety net, yet the sudden evaporation of royalty income from Alexion introduces a level of uncertainty that cannot be ignored. The tension between the bull and bear cases centers on whether the current liquidity is a bridge to commercial success or a slowing descent toward a capital crisis. Ultimately, the filing highlights a company in transition. The shift toward a more diversified pipeline and the reliance on partner-led filings for Monjuvi and obexelimab move the needle from internal burn to external validation. Investors must now weigh the strength of the $541.8 million liquidity pool against the structural risks of royalty disputes and the high cost of servicing royalty-sale debt.